Inhibition of extracellular HMGB1 attenuates inflammation and confers protection in several animal models of experimental diseases including sepsis [30], cardiac and liver ischemia/reperfusion injury [38, 39], diabetes [40], autoimmune diseases [41] and epilepsy [42]. This evidence concerns the gene HMGB1 and diabetes mellitus.